uploads/2018/06/PAH.png

Johnson & Johnson’s Pulmonary Hypertension Business

By

Updated

Pulmonary Hypertension segment’s revenue trends

In June 2017, Johnson & Johnson’s (JNJ) acquisition of Actelion led to the establishment of its Pulmonary Hypertension segment. In the first quarter, this segment reported revenues of $585.0 million. This included revenues of $361.0 million and $224.0 million from its sales in the US and international markets, respectively.

Article continues below advertisement

Opsumit’s revenue trends

In the first quarter, Johnson & Johnson’s Opsumit reported revenues of $271.0 million. This included revenues of $149.0 million and $122.0 million from its sales in the US and international markets, respectively.

In April, Johnson & Johnson submitted a supplemental New Drug Application (or sNDA) to the FDA for the label expansion of Opsumit. This label expansion would include its use for the treatment of adult individuals with inoperable chronic thromboembolic pulmonary hypertension. It would also be used for the improvement of exercise capacity and pulmonary vascular resistance (or PVR).

The FDA sNDA was based on the data from the MERIT-1 trial. In the MERIT-1 trial, Opsumit demonstrated improvements in the primary endpoint of PVR and secondary endpoint of 6MWD (or six-minute walk distance) compared to placebo therapy.

Opsumit also demonstrated that its well-tolerability and safety profile remained consistent with the known safety profile of Opsumit according to prior clinical trials.

Tracleer and Uptravi: Revenue trends

In the first quarter, Tracleer reported revenues of $140.0 million, which included $68.0 million and $72.0 million from the US and international markets, respectively.

In the first quarter, Uptravi generated revenues of $140.0 million, including revenues of $124.0 million and $16.0 million, respectively, from the sales in the US and international markets.

In the marketplace, Johnson & Johnson’s Pulmonary Hypertension segment faces stiff competition from Pfizer’s (PFE) Norvasc, Bayer’s (BAYZF) Adempas, United Therapeutics’ (UTHR) Remodulin and Orenitram, and Gilead Sciences’ (GILD) Letairis. Norvasc, Remodulin, Orenitram, and Letairis reported first-quarter revenues of $254.0 million, $127.0 million, $52.0 million, and $204.0 million, respectively

Advertisement

More From Market Realist